Real estate is the next big catalyst for marijuana stocks in 2017, as more voters demand legalized recreational and medical cannabis in their states.
Prices are tumbling as formerly illicit cultivators emerge from the shadows to invest millions of dollars in massive pot factories. In Colorado, the average price sought by wholesalers has fallen 48 per cent to about US$1,300 a pound since legal sales to all adults started in January 2014, according to Cannabase, operator of the state’s largest market.. Supply is surging as growers expand and install the latest agricultural technology.
A comprehensive study slams many of the alleged benefits of marijuana and points to serious negative effects. What will the impact of this study be for marijuana stocks?
Canopy Growth Corp. (TSX:CGC) has been on a wild ride in recent months, and investors who think the name has long-term potential are trying to decided when they should buy.
U.S. estimates by investment bank Cowen and Company suggest cannabis sales will increase at a compound annual growth rate of 23% over the next decade to US$50 billion. In Canada, it’s estimated that 5.2 million Canadians will consume legalized pot annually by 2021.
Anandia Labs co-founder Jonathan Page agreed to sell 20% of his company to CannaRoyalty because he appreciates CannaRoyalty’s expertise in extraction and post-processing.
On Jan. 6, 2017, CB Insights released a report on annual funding activity for private marijuana companies in 2016, as well as activity for the fourth quarter of the year. According to the report, deals made and dollars invested leveled off in 2016.
As Cannabis Science Inc (OTCMKTS:CBIS) goes forward into 2017 with its stock, the company recently announced about its new drug facility in Nevada.
MassRoots Inc(OTCMKTS:MSRT) describes itself as one of the largest technology platforms for the regulated cannabis industry. MSRT is at the right place at the right time as the pot sector has been seeing huge growth in recent months as medical MJ products in the U.S. alone are projected to generate up to $35 Billion by 2020.
Sales in the legal marijuana industry are skyrocketing, which is why Money Morning created a list of the top marijuana stocks to watch in 2017. But because marijuana is still illegal under federal law, and many of the marijuana stocks on the market are so volatile, this isn’t a list of recommendations. Rather, it’s a list of marijuana stocks they are watching closely in 2017.
Further details of recall revealed that there has been a detection of an unwanted pesticide, which is not registered for use on marijuana, under the Pest Control Products Act.
Most myths have at least a little bit of truth interspersed with a lot that is false. That’s the case with these three myths about marijuana stocks that some might mistakenly believe.
CanniMed Therapeutics Inc. became the latest and last medical marijuana company Thursday to go public in 2016, capping off a banner year in the burgeoning sector.
Here are three stocks that have doubled investors’ money in 2016, and a look into whether or not they can continue to rally in 2017.
In the last few months, the medical marijuana growers have dominated the trading activity on the TSX Venture in terms of dollar volume almost exclusively, belying a persistent interest from investors in Canada and the United States.
Canopy, previously listed on the Canadian Venture Exchange under stock symbol TWD (Tweed was the original company, later consolidated into Canopy), began trading publicly on the Toronto Stock Exchange in July amid great anticipation from investors and financial markets.
Shares of industrial warehouse companies such as Prologis Inc, Rexford Industrial Realty Inc and Terreno Realty Corp that have significant exposure to the California market should benefit even if they do not lease to marijuana companies directly, fund managers and analysts say.
While many investors were drawn in by the myth that millions would be made by investing in the companies that purportedly planned to cultivate and sell medical and leisure based marijuana, they should have been focused on investing in companies that are intent on utilizing the plant’s cannabinoid properties, which are consistently demonstrating extraordinary benefit in treating a host of medical conditions.
MassRoots Inc is a penny play in the cannabis space on the technology side that has been performing extremely well of late on several key catalysts.
The company said the 74,000-square-metre facility, called Aurora Sky, will be larger than 16 football fields and will be capable of producing more than 100,000 kilograms of cannabis per year.
The fed’s report was largely positive for the recreational marijuana industry when it was released Tuesday. Aurora Cannabis stock was one of the biggest pot stock beneficiaries of the announcement, but has since had a regression in share price.
Institutions need information in order to make decisions. A big part of the information they need to measure and predict outcomes is in the data, but real information is the convergence of that data with sound analysis.
Pot stocks got a lift Tuesday following the issue of a task force report with recommendations on recreational pot sales.
Scientists, regulators and millions suffering from pain are trying to get their hands on cannabis — but not the kind you smoke, eat or grow in an alley.
If you’re considering investing in marijuana stocks in the new year, here are five numbers you should know before taking the plunge.
For the purpose of this column we consider three types of institutions: government, academic and corporate. They are the thought leaders, market leaders and mainstream actors from outside the industry that are stakeholders in the effects of an economic outcome.
Let’s take a look back on this past year and see what the future holds for marijuana stocks.
For now, CannaRoyalty is also the only option for Canadian investors to gain exposure to the U.S. recreational marijuana market.
Institutional interest is emerging. Data has become available and it’s time to start telling the story of the marijuana economy.
According to a report by the equity research firm Cowen & Co., marijuana will generate $50 billion in revenue by 2026. That’s roughly eight times the estimated revenue this year. GW Pharmaceuticals and Insys Therapeutics are two big companies with an even bigger future.
North American Cannabis Holdings, Inc. (USMJ) today issued a statement advising shareholders of an event-filled December.
Innovative Industrial Properties, Inc. (IIPR) is one of the latest and most notable companies focusing on marijuana to hit the markets, and the company had a fairly quiet IPO on Thursday, December 1.
Is Canopy Growth about to become a mega marijuana stock company?
With several states passing measures to legalize marijuana in 2016, the cannabis business looks poised to finally to take off. But for investors, there remains a quandary: How do you find a way to get in on the ground floor of this new growth industry?
On Nov. 21, 2016, Kaya Holdings (OTCQB:KAYS), whose subsidiary Kaya Shack opened its first cannabis dispensary in Portland, Oregon, in 2014, announced that it had filed its third quarterly report of 2016, reporting a 700% year-over-year revenue increase.
On Nov. 21, 2016, rapper and actor Jayceon Terrell Taylor, known on stage as The Game, announced in an Instagram post that he is launching an investment fund to invest in the legal cannabis industry.
Are you an entrepreneur eager to fund your cannabis business? Needless to say, banks are not going to be your first choice. How can you raise capital legally and then bank the money you make?
On Nov. 4, 2016, Privateer Holdings, a Seattle-based private equity firm focused on the legal cannabis industry, announced that it has closed $40 million in convertible bridge funding, the first part of a future $100 million Series C equity round.
On Nov. 3, 2016, Kush Bottles (OTCQB:KSHB), a supplier of packaging solutions and accessories for the legal cannabis industry, announced that it logged a record-breaking annual revenue of approximately $8.2 million for the fiscal year ended on Aug. 31.
On Oct. 28, 2016, hundreds of interested investors and contractors attended a public medical marijuana forum hosted by the Louisiana State University Agricultural Center, one of two state-sanctioned medical marijuana cultivators.
On Oct. 25, 2016, Eaze, a medical marijuana delivery service in California, announced that it had completed a $13 million Series B round of financing, bringing the company’s fundraising total to $25 million.
Creso Pharma shares jumped when the medical cannabis company debuted on the ASX. The shares are up by a quarter since listing on Thursday at 25 cents.
On Oct. 18, 2016, CB Insights released a report on deals made and dollars invested into private American cannabis companies in the third quarter of 2016. Deals remained steady for the quarter, but dollars invested dropped to the lowest recorded level since Q3 of 2015.
New Cannabis Ventures broke the news Monday evening. It will be the first publicly-traded cannabis-related Real Estate Investor Trust or REIT and, if approved, would be the first cannabis company to be traded at the venerable NYSE.
Washington, D.C.-based startup New Frontier Data has almost completed a $5 million funding round to expand its work doing data and analytics for the legal marijuana industry.
For investors, the rising prospects of legalized pot may be too good to pass up, yet the publicly traded cannabis companies may not be such a smart bet.
On Oct. 7, 2016, the Louisiana State University Agricultural Center announced that it will hold a public forum on Oct. 28 to discuss Louisiana’s medical marijuana program as it concerns the LSU AgCenter.
On Sept. 26, 2016, GW Pharmaceuticals (Nasdaq:GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for its third study in the United States on the efficacy of Epidiolex, its experimental CBD-based drug, in treating seizures associated with Lennox-Gastaut syndrome.
On Sept. 26, 2016, Massroots (OTCQB:MSRT) issued a letter from Isaac Dietrich, Chairman and Chief Executive Officer, on the company’s outlook for Fall 2016, including updates on the product pipeline, user growth and expense reductions, among others; however, the letter failed to address the company’s recent default on debt.
Bloomfield Industries, one of the five organizations licensed by the state of New York to cultivate and distribute medical marijuana, is facing “financial constraints.”